Drug Resistance — When Treatments Stop Working

In biological terms, drug resistance is divided into intrinsic (primary) resistance, where the cancer does not respond to therapy from the outset, and acquired (secondary) resistance, where a tumour initially shrinks or stabilises but subsequently resumes growth after adapting to the therapeutic pressure.

At the cellular level, resistance arises through genetic mutations, epigenetic alterations, and clonal evolution. Tumour cells may upregulate efflux pumps to expel drugs, alter target receptor proteins so medicines can no longer bind, activate alternate compensatory signaling pathways, or evade programmed cell death (apoptosis). The natural heterogeneity of tumours means that drug exposure often selectively eliminates sensitive cells while permitting resistant sub-clones to expand.

Recognising the mechanisms of drug resistance empowers you to understand why routine monitoring scans and blood tests are carried out even when you feel well. It clarifies why cancer therapies are frequently combined or altered over time. If your cancer demonstrates resistance to a particular drug, your oncology team can use this information to change course, selecting alternative treatments, targeted drugs, or clinical trials designed to bypass that specific resistance pathway.

Identifying resistance mechanisms often involves repeat tumour biopsies or minimally invasive liquid biopsies (blood tests assessing circulating tumour DNA). Genetic sequencing platforms, such as Next-Generation Sequencing (NGS), look for specific secondary mutations—such as the EGFR T790M or C797S mutations in lung cancer, or ESR1 mutations in breast cancer. Regular imaging scans (CT, PET, MRI) assess whether tumour dimensions are growing despite continued medication.

Drug resistance can occur across nearly all cancer types, especially advanced or metastatic conditions. It is notably observed in EGFR-mutant or ALK-rearranged non-small cell lung cancer, hormone receptor-positive metastatic breast cancer treated with endocrine therapies, BRAF-mutated melanoma treated with targeted kinase inhibitors, castration-resistant prostate cancer, and chronic myeloid leukaemia.

When resistance is identified, oncologists modify the treatment strategy. This may involve switching to next-generation targeted drugs engineered to overcome specific secondary mutations (for example, using osimertinib after first-generation EGFR inhibitors fail). In other instances, doctors combine therapies to attack multiple signaling pathways simultaneously, or transition the patient to immunotherapy, cytotoxic chemotherapy, or novel clinical trial regimens.